Clinical Impact of CYP450 Polymorphisms on Antidepressant Efficacy

Cytochrome P450 (CYP450) enzymes play a critical role in the metabolism of many antidepressants, influencing both the efficacy and safety of these medications. Genetic polymorphisms in CYP450 genes, such as CYP2D6, CYP2C19, and CYP1A2, lead to variations in enzyme activity, which can significantly affect drug plasma levels and, consequently, treatment outcomes. This review examines the clinical impact of CYP450 polymorphisms on antidepressant efficacy, focusing on common variants and their associations with altered drug metabolism. We explore the role of genetic testing in predicting individual responses to selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and other antidepressant classes. The findings suggest that pharmacogenomic-guided therapy could enhance treatment outcomes by reducing trial-and-error prescribing, minimizing adverse effects, and optimizing therapeutic efficacy. However, challenges such as the need for widespread genetic screening, cost, and clinical integration remain. The article concludes with a discussion of the potential for personalized antidepressant therapy based on CYP450 genotyping to improve patient care.